Diabetes, Vol 40, Issue 6 715-725, Copyright © 1991 by American Diabetes Association

ARTICLES

Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice

MF McInerney, SB Pek and DW Thomas
Department of Microbiology and Immunology, University of Michigan, Ann Arbor.

In studies of immune cell defects in autoimmune diabetes mellitus, we observed that complete Freund's adjuvant (CFA) prevented the onset of diabetes when injected into 8- to 10-wk-old prediabetic nonobese diabetic (NOD) mice. The prevalence of the onset of diabetes in the CFA-injected versus uninjected NOD mice was 2 of 81 (2.5%) vs. 231 of 379 (61%) among females and 2 of 44 (4.5%) vs. 83 of 336 (25%) among males, respectively. The incidence of histologically identifiable insulitis was significantly reduced in CFA-treated prediabetic female NOD mice (18%) compared with the incidence in female age-matched controls (70%). Splenocytes or Mac-(1+)-enriched splenocytes from CFA-treated NOD mice, when cotransferred with splenocytes from diabetic mice, reduced the incidence of diabetes provoked by diabetic splenocytes in vivo. In the spleen, CFA injection induced sustained increases in cell proliferation and an associated major increase in the numbers of an immature cell type that expressed the Mac-1 surface antigen. In CFA-treated NOD mice, lymphocytes derived from the spleen failed to respond in vitro to stimulation by the mitogen concanavalin A or by anti-CD3. When cocultured, Mac-1+ cells, enriched from the splenocytes of CFA-treated mice, suppressed concanavalin A- or anti-CD3-induced proliferation of T lymphocytes derived from either the spleen or thymus of untreated NOD mice. Therefore, treatment with CFA prevents the development of diabetes, and concomitantly, insulitis while stimulating the generation of splenic suppressor cells that are capable of suppressing diabetogenic T-lymphocyte function in vivo and in vitro.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. M. Filippi and M. G. von Herrath Viral Trigger for Type 1 Diabetes: Pros and Cons Diabetes, November 1, 2008; 57(11): 2863 - 2871. [Full Text] [PDF]

				A. Suri and E. R Unanue Response to Comment on Suri et al. on Diabetes Reversal in NOD Mice Science, November 24, 2006; 314(5803): 1243d - 1243d. [Abstract] [Full Text] [PDF]

				D. Ly, Q.-S. Mi, S. Hussain, and T. L. Delovitch Protection from Type 1 Diabetes by Invariant NK T Cells Requires the Activity of CD4+CD25+ Regulatory T Cells J. Immunol., September 15, 2006; 177(6): 3695 - 3704. [Abstract] [Full Text] [PDF]

				A. Suri, B. Calderon, T. J. Esparza, K. Frederick, P. Bittner, and E. R. Unanue Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells. Science, March 24, 2006; 311(5768): 1778 - 1780. [Abstract] [Full Text] [PDF]

				Y.-G. Chen, C.-M. Choisy-Rossi, T. M. Holl, H. D. Chapman, G. S. Besra, S. A. Porcelli, D. J. Shaffer, D. Roopenian, S. B. Wilson, and D. V. Serreze Activated NKT Cells Inhibit Autoimmune Diabetes through Tolerogenic Recruitment of Dendritic Cells to Pancreatic Lymph Nodes J. Immunol., February 1, 2005; 174(3): 1196 - 1204. [Abstract] [Full Text] [PDF]

				I-F. Lee, H. Qin, J. Trudeau, J. Dutz, and R. Tan Regulation of Autoimmune Diabetes by Complete Freund's Adjuvant Is Mediated by NK Cells J. Immunol., January 15, 2004; 172(2): 937 - 942. [Abstract] [Full Text] [PDF]

				K. V. Tarbell, M. Lee, E. Ranheim, C. C. Chao, M. Sanna, S.-K. Kim, P. Dickie, L. Teyton, M. Davis, and H. McDevitt CD4+ T Cells from Glutamic Acid Decarboxylase (GAD)65-specific T Cell Receptor Transgenic Mice Are Not Diabetogenic and Can Delay Diabetes Transfer J. Exp. Med., August 19, 2002; 196(4): 481 - 492. [Abstract] [Full Text] [PDF]

				A. Billiau and P. Matthys Modes of action of Freund's adjuvants in experimental models of autoimmune diseases J. Leukoc. Biol., December 1, 2001; 70(6): 849 - 860. [Abstract] [Full Text] [PDF]

				A. Quinn, M. F. McInerney, and E. E. Sercarz MHC Class I-Restricted Determinants on the Glutamic Acid Decarboxylase 65 Molecule Induce Spontaneous CTL Activity J. Immunol., August 1, 2001; 167(3): 1748 - 1757. [Abstract] [Full Text] [PDF]

				D. A. Kahn, D. C. Archer, D. P. Gold, and C. J. Kelly Adjuvant Immunotherapy Is Dependent on Inducible Nitric Oxide Synthase J. Exp. Med., June 4, 2001; 193(11): 1261 - 1268. [Abstract] [Full Text] [PDF]

				A. M. Girvin, M. C. Dal Canto, L. Rhee, B. Salomon, A. Sharpe, J. A. Bluestone, and S. D. Miller A Critical Role for B7/CD28 Costimulation in Experimental Autoimmune Encephalomyelitis: A Comparative Study Using Costimulatory Molecule-Deficient Mice and Monoclonal Antibody Blockade J. Immunol., January 1, 2000; 164(1): 136 - 143. [Abstract] [Full Text] [PDF]

				D. Elias, Y. Tikochinski, G. Frankel, and I. R. Cohen Regulation of NOD mouse autoimmune diabetes by T cells that recognize a TCR CDR3 peptide Int. Immunol., June 1, 1999; 11(6): 957 - 966. [Abstract] [Full Text] [PDF]